{"id":"ql1206","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"QL1206 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. This mechanism is particularly effective in treating type 2 diabetes.","oneSentence":"QL1206 is a small molecule drug that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:59.592Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07062978","phase":"PHASE3","title":"A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-06-27","conditions":"Postmenopausal Women With Osteoporosis at High Risk of Fracture","enrollment":278},{"nctId":"NCT04934072","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 in Postmenopausal Women With Osteoporosis","status":"COMPLETED","sponsor":"Fresenius Kabi SwissBioSim GmbH","startDate":"2021-06-16","conditions":"Postmenopausal Osteoporosis","enrollment":553},{"nctId":"NCT05299073","phase":"PHASE1","title":"A Study Comparing the Pharmacokinetic Similarity of MB09 and EU/US-Sourced Xgeva","status":"COMPLETED","sponsor":"mAbxience Research S.L.","startDate":"2022-03-01","conditions":"Healthy Volunteers","enrollment":257},{"nctId":"NCT02470091","phase":"PHASE2","title":"Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2015-11-21","conditions":"Metastatic Osteosarcoma, Recurrent Osteosarcoma, Refractory Osteosarcoma","enrollment":56},{"nctId":"NCT03382574","phase":"EARLY_PHASE1","title":"Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-03-14","conditions":"Ovarian Carcinoma","enrollment":2},{"nctId":"NCT04550949","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2019-04-26","conditions":"Bone Metastases","enrollment":700},{"nctId":"NCT04213105","phase":"PHASE1","title":"Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Prolia® in Healthy Adults","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2019-10-31","conditions":"Healthy People","enrollment":144},{"nctId":"NCT04128163","phase":"PHASE3","title":"Efficacy and Safety of QL1206 in the Treatment of Postmenopausal Osteoporosis With High Fracture Risk","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2019-06-05","conditions":"Postmenopausal Osteoporosis","enrollment":440},{"nctId":"NCT03651947","phase":"PHASE1","title":"Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults","status":"COMPLETED","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2018-08-20","conditions":"Healthy People","enrollment":168}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Recombinant anti-RANKL human monoclonal antibody injection","recombinant human anti-RANKL monoclonal antibody injection"],"phase":"phase_3","status":"active","brandName":"QL1206","genericName":"QL1206","companyName":"Qilu Pharmaceutical Co., Ltd.","companyId":"qilu-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"QL1206 is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":4,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}